BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16629826)

  • 1. A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
    Seierstad M; Agrafiotis DK
    Chem Biol Drug Des; 2006 Apr; 67(4):284-96. PubMed ID: 16629826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of an in silico model for hERG binding.
    Song M; Clark M
    J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
    Moorthy NS; Ramos MJ; Fernandes PA
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification models for HERG inhibitors by counter-propagation neural networks.
    Thai KM; Ecker GF
    Chem Biol Drug Des; 2008 Oct; 72(4):279-89. PubMed ID: 18844674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
    Leong MK
    Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR.
    Johnson SR; Yue H; Conder ML; Shi H; Doweyko AM; Lloyd J; Levesque P
    Bioorg Med Chem; 2007 Sep; 15(18):6182-92. PubMed ID: 17596950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An automated docking protocol for hERG channel blockers.
    Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
    J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bias-correction of regression models: a case study on hERG inhibition.
    Hansen K; Rathke F; Schroeter T; Rast G; Fox T; Kriegl JM; Mika S
    J Chem Inf Model; 2009 Jun; 49(6):1486-96. PubMed ID: 19435326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of hERG potassium channel affinity by the CODESSA approach.
    Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
    Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
    Nisius B; Göller AH; Bajorath J
    Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.